Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same author

A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2026
Same author

Complications of PI to PIII hemipelvic resections for intermediate and malignant tumours : a systematic review and meta-analysis.

Bone & joint open·2026
Same author

Team Approach: Diagnosis and Management of Pediatric Pelvic Ewing Sarcoma.

JBJS reviews·2026
Same author

Sex differences in physical activity, psychosocial determinants, and symptom outcomes in knee osteoarthritis: a cross-sectional analysis of a Hispanic/Latino-predominant cohort.

Rheumatology international·2026
Same author

IlluminOss photodynamic bone stabilization system: Retrospective cohort review of clinical and peri-operative imaging complications.

Clinical imaging·2026
Same journal

Comparative Analysis of CEM and Breast MRI: A Retrospective Study.

Journal of surgical oncology·2026
Same journal

The Treatment Efficacy for Patients Undergoing Combined Transanal-Transabdominal Endoscopic Resection of Rectal Anastomosis Stenosis.

Journal of surgical oncology·2026
Same journal

"It Depends on the Situation": Variability in How Surgical Oncologists Elicit and Integrate Patient Values.

Journal of surgical oncology·2026
Same journal

A Tale of Two Pathways: Same-Surgeon Versus Different-Surgeon Resection After Second Surgical Opinion.

Journal of surgical oncology·2026
Same journal

How I Do It: The Life and Work of a Rubber Band in Robotic Liver Parenchymal Transection.

Journal of surgical oncology·2026
Same journal

New Paradigms of Cancer Require New Language: A Qualitative Study Exploring Language for Non-Curative Non-Palliative Cancer Surgery.

Journal of surgical oncology·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2025

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.2K

Brachytherapy for Soft Tissue Sarcoma: Maintaining Local Control While Minimizing Complications.

Julien Montreuil1, Eric Kholodovsky2, Moses Markowitz2

  • 1Department of Orthopaedics, University of Miami Miller School of Medicine, Miami, Florida, USA.

Journal of Surgical Oncology
|November 19, 2024
PubMed
Summary
This summary is machine-generated.

High-dose brachytherapy (BRT) offers a lower risk of wound complications compared to neoadjuvant external beam radiation therapy (Neo-EBRT) for soft tissue sarcomas, with similar local control rates.

Keywords:
brachytherapysoft tissue sarcomawound complications

More Related Videos

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.1K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K

Related Experiment Videos

Last Updated: Jun 7, 2025

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.2K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.1K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Surgical Oncology

Background:

  • High-grade soft tissue sarcomas require effective treatment strategies.
  • Comparing different radiation modalities is crucial for optimizing patient outcomes.
  • Brachytherapy (BRT) and external beam radiation therapy (EBRT) are key treatment options.

Purpose of the Study:

  • To compare clinical and oncologic outcomes of BRT versus preoperative and postoperative EBRT.
  • To evaluate the efficacy and safety of different radiation techniques in soft tissue sarcoma treatment.
  • To identify optimal radiation strategies based on patient and disease characteristics.

Main Methods:

  • Retrospective cohort study of 144 patients with soft tissue sarcoma.
  • Analysis of patients treated with BRT, neoadjuvant EBRT (Neo-EBRT), or adjuvant EBRT (AD-EBRT).
  • Comparison of wound complications and local recurrence (LR) rates across treatment groups.

Main Results:

  • Neo-EBRT group had a significantly higher incidence of wound complications (50%) compared to BRT (25%) and AD-EBRT (28.3%).
  • Multivariate analysis confirmed increased wound complication risk with Neo-EBRT versus BRT (p=0.007).
  • No significant difference in local recurrence (LR) risk was observed between the treatment groups (p=0.28).

Conclusions:

  • Brachytherapy is a valuable treatment for soft tissue sarcomas, offering clinical and logistical benefits.
  • BRT demonstrates a lower risk of wound complications compared to Neo-EBRT.
  • Brachytherapy provides comparable local control to EBRT, making it a favorable option in specific scenarios.